Epizyme Revenue and Competitors
Estimated Revenue & Valuation
- Epizyme's estimated annual revenue is currently $34.2M per year.
- Epizyme's estimated revenue per employee is $126,741
- Epizyme's total funding is $834.1M.
- Epizyme's current valuation is $225.5M. (January 2022)
Employee Data
- Epizyme has 270 Employees.
- Epizyme grew their employee count by -28% last year.
Epizyme's People
| Name | Title | Email/Phone |
|---|---|---|
1 | Senior Director, Field Medical Training & Development | Reveal Email/Phone |
2 | East Region Director, Field Medical Affairs | Reveal Email/Phone |
3 | Associate Director, Clinical Data Management | Reveal Email/Phone |
4 | Director, Biology | Reveal Email/Phone |
5 | Associate Director Epigenetic Therapy | Reveal Email/Phone |
6 | Senior Director, Regulatory Affairs CMC | Reveal Email/Phone |
7 | Director, Thought Leader Engagement, Hematology / Oncology / Rare Disease | Reveal Email/Phone |
8 | Senior Manager Clinical Data Management | Reveal Email/Phone |
9 | Senior Manager, Forecasting, Analytics and New Product Planning | Reveal Email/Phone |
10 | Senior HRIS and Compensation Manager | Reveal Email/Phone |
Epizyme Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $5.4M | 35 | 3% | N/A | N/A |
#10 | $1.6M | 10 | 0% | N/A | N/A |
What Is Epizyme?
Epizyme, Inc. is a late-stage biopharmaceutical company rewriting therapy for cancer and other serious diseases through novel epigenetic medicines. Our pipeline is led by tazemetostat, an investigational agent that is an orally administered, first-in-class small molecule EZH2 inhibitor for the treatment of multiple types of hematological malignancies and genetically defined solid tumors. The company also is developing a novel G9a program with its next development candidate, EZM8266, which is targeting sickle cell disease. By focusing on the genetic drivers of disease, Epizyme's science seeks to match targeted medicines with the patients who need them.
keywords:N/A
$834.1M
Total Funding
270
Number of Employees
$34.2M
Revenue (est)
-28%
Employee Growth %
$225.5M
Valuation
N/A
Accelerator
Epizyme News
Epizyme: Epizyme Inc. (Nasdaq: EPZM) revealed in its fourth-quarter 2021 earnings report that it had let go of about 12% of its employees,...
Epizyme Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). April 06, 2022 07:00 AM Eastern Daylight Time. CAMBRIDGE, Mass.--(BUSINESS...
Epizyme (NASDAQ:EPZM) Chief Medical and Development Officer ... Year to date through Wednesday's close, Epizyme (EPZM) shares are down ~68%.
Shares of Epizyme rose 35.6% on the Nasdaq Wednesday following the news, before leveling off and by Thursday afternoon trading at around 8% above their Wednesday closing price. “We are incredibly pleased by ODAC’s unanimous support for the benefit-risk of tazemetostat in ES, and we appreciate t ...
Epizyme, Inc. (Nasdaq: EPZM), a Cambridge, Mass.-based late-stage biopharmaceutical company developing novel epigenetic therapies, closed funding agreements that, in aggregate, could bring in up to $270m in capital. The backers were Royalty Pharma and its affiliate Pharmakon Advisors. As part o ...
Other Companies in Cambridge
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $30.3M | 270 | 6% | N/A |
#2 | $24.5M | 271 | -5% | $656.6M |
#3 | $79.8M | 275 | -1% | $3M |
#4 | $81.7M | 275 | -18% | N/A |
#5 | $62.8M | 278 | 47% | $240.8M |